Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | FPR3 | P25089 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599951 | 0.90 | TDP1 (0.52) | CA1CA2KMT2AGAAMEN1 | |
| SCHEMBL4599955 | 0.90 | TDP1 (0.52) | CA1CA2KMT2AGAAMEN1 | |
| SCHEMBL6287916 | 0.89 | CA1 (0.48) | CA1CA2KMT2AGAAMEN1 | |
| SCHEMBL6287020 | 0.89 | CA1 (0.48) | CA1CA2KMT2AGAAMEN1 | |
| SCHEMBL20067638 | 0.88 | SPHK1 (0.49) | CA1CA2KMT2AGAAMEN1 | |
| SCHEMBL30746081 | 0.85 | DPP8 (0.48) | CA1CA2KMT2AMEN1MAPT | |
| SCHEMBL2928021 | 0.85 | MEN1 (0.53) | CA1CA2KMT2AGAAMEN1 | |
| SCHEMBL21097234 | 0.84 | ANPEP (0.49) | CA1CA2KMT2AGAATDP1 | |
| SCHEMBL28432531 | 0.83 | CA1 (0.48) | CA1CA2KMT2AGAAMEN1 | |
| SCHEMBL19931686 | 0.82 | CA1 (0.49) | CA1CA2KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3191135-B1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. | 2020-02-11 | — | — | US | disclosed |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10179820-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10017577-B2 | Antibodies and immunoconjugates | GENENTECH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3307780-A1 | ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3191135-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2016205176-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-9518118-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016040723-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179820-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885KMT2A 857/4885 |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885KMT2A 857/4885 |
| US-10017577-B2 | Antibodies and immunoconjugates | FCGR3B, CD47, FCGR1A | CA1 1600/4885CA2 3167/4885KMT2A 2491/4885 |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885KMT2A 857/4885 |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885KMT2A 857/4885 |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885KMT2A 857/4885 |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885KMT2A 857/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885KMT2A 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.